New Approaches to the Treatment of Uncomplicated Urinary Tract Infections

Abstract

The most common cause of uncomplicated urinary tract infections is acute cystitis. This is the most common reason for visiting a urologist among women of young and middle age. At the same time, the number of relapses of the disease remains very significant and, as a rule, is explained by ineffective antibiotic therapy.The objective: to analyze the effectiveness and safety of the use of the immunoactive drug Urivak in complex therapy in patients with acute, including recurring cystitis, after a course of antibiotic therapy as an anti-relapse/prophylactic agent.Materials and methods. The study included 58 women who turned to a urologist in connection with acute cystitis. Patients were divided into two groups. In the control group (n = 25), women received antibiotic therapy, in the main group (n = 33) - antibiotic therapy followed by prophylactic administration of the Urivak vaccine.Results. In the 1st (control) group, after 10 days of antibiotic therapy (ABT), the patients were followed up for another 3 months. Moreover, the number of relapses was 8% already in the first month and increased to 32% by the end of the study. In the main group, after ABT, patients received treatment with Urivak according to the scheme: 10 days, 1 capsule per day every first decade for 3 months.Conclusion. The use of the immunoactive drug Urivak in the complex treatment of uncomplicated urinary tract infections has reduced the number of relapses to 9% within 3 months.